Noam Karstaedt
President

Noam has been an active member of the Israeli venture capital community for more than 10 years, and in 1992 helped pioneer Israel's first life science VC fund, MedMax Ventures. Noam's formal education includes a Masters degree in Applied Mathematics and Engineering from Witwatersrand University in South Africa and an MBA from the Graduate School of Business at Stanford University. Noam has held numerous consulting and management positions both in Israel and the United States and he was a strategic management consultant at the San Francisco office of Booz, Allen & Hamilton.
Mr. Karstaedt is skilled at successful investing and was part of the management team responsible for the funding of ESC, which is regarded as one of the most prosperous Life Science VC investments in Israel's history, returning more then $150 million on an initial investment of $1M. As President of Denali Ventures, Noam places his extensive formal knowledge of finance and administration and his significant network of contacts behind all portfolio investments. He is recognized as an aggressive supporter of start-up companies in the Israeli life science environment.
Email: Noam@DenaliVC.com

Yael Margolin, Ph.D. 
Vice President

Yael Margolin combines a broad scientific education with extensive industry experience. She holds M.Sc. in Microbiology from Tel Aviv University, a Ph.D. in Biochemistry from the Weizmann Institute of Science, and was a postdoctoral associate at the Yale University School of Medicine. Yael's formal education at the business management program of the Tel Aviv University Business School is complemented by 10 years of industrial experience at Teva Pharmaceutical Industries, the largest pharmaceutical company in the Middle East, with a market cap of $8 billion. At Teva, Dr. Margolin was predominantly responsible for evaluating investment opportunities for the R&D division as well as for multiple drug development programs. Yael joined Denali Ventures in 1998, where she focuses on pharmaceutical developments and biotechnology.
Email: Yael@DenaliVC.com

Ronny Ginor, M.D.
Vice President

Ron is a graduate of the Elliot School of International Affairs with a degree in International Economics and The George Washington University School of Medicine. After publishing postgraduate research work at The Memorial Sloan Kettering Cancer Center and completing an A.I. in Radiation Oncology at Stanford University, Dr. Ginor combined his clinical and industrial experience in a number of management and consulting positions. In 1997 Ron moved to Israel in order to become Director of Clinical Research and Medical Development at Medinol Ltd., a recognized leader in the cardiovascular technology market. While at Medinol, Ron was responsible for the development of clinical protocols, as well as for interaction with the FDA, European regulatory agencies and key international partners including Boston Scientific. At Denali Ventures, Ron focuses predominantly on medical devices, vascular technologies, computerized medical platforms, and international regulatory issues
Email: Ronny@DenaliVC.com